Neuropeptides, Social Stress and Drugs of Abuse
神经肽、社会压力和滥用药物
基本信息
- 批准号:9238287
- 负责人:
- 金额:$ 33.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-01 至 2021-11-30
- 项目状态:已结题
- 来源:
- 关键词:Accident and Emergency departmentAgonistAlcoholsBehavioralBinding ProteinsBrainBuffersCRH geneCellsCocaineCocaine AbuseCorticotropin-Releasing HormoneCriminal JusticeDataDopamineDoseDrug usageDrug userEndocrineEpidemiologyExposure toExtinction (Psychology)FemaleGeneticHumanHypothalamic structureInterventionLearningLinkMaintenanceMediatingMethodologyMethodsMicrodialysisMicroinjectionsModelingMusNeurobiologyNeuronsNeuropeptidesPeptidesPharmaceutical PreparationsPharmacologyPhaseProcessPunishmentRattusRelapseReportingResearchResistanceResolutionRewardsRodentSelf AdministrationSourceStressSynapsesSystemTestingTherapeutic InterventionTranslatingVentral Tegmental AreaViolenceViral VectorWorkaddictionbasebiological adaptation to stressdopamine systemdopaminergic neurondorsal raphe nucleusdrug abuse therapydrug of abuseeffective therapyin vivointerestmaleneuroadaptationneurochemistrynonhuman primatenoveloptogeneticspreventprogramssexsocialsocial stressstatisticsstress disordertargeted treatmenttoolviolent crime
项目摘要
Project Summary
The rationale for the current specific aims builds on the consistent epidemiological finding that social
stress contributes critically to all phases of the addiction cycle, from initiation to escalation to relapse. The
close link between social stress and drug use is based on reports from emergency rooms treating victims of
violence and statistics from the criminal justice system on violent crimes committed by drug users as well as
epidemiological evidence and neurobiological data. The overarching question to be answered by the proposed
research is: what is the mechanistic link between social stress and escalated cocaine self-administration? Our
special emphasis is on how corticotropin releasing factor (CRF, often referred to as CRH) modulates
mesocorticolimbic dopamine (DA) systems. The CRF system is of continued interest, not only because it is
critical to the initiation of the endocrine stress response, but its extra-hypothalamic localization and action are
of significance in stress disorders and represent potential targets for therapeutic intervention.
Specific Aim One tests the hypothesis that highly aversive social stress amplifies intensely rewarding
cocaine self-administration by action on CRF and dopamine (DA) in microcircuits from the posterior ventral
tegmental area (pVTA) to the dorsal raphe nuclei (DRN). Neuroanatomical tract tracing is employed to identify
the synaptic contacts with DA neurons as a source of CRF input. In vivo microdialysis in the terminals of these
microcircuits are used to characterize the dynamic neuroadaptions that contribute to the stress-induced
escalation of cocaine self-administration (acquisition, maintenance, binge, relapse).
Specific Aim Two tests the hypothesis that activation and inhibition of specific CRF cell groups in the VTA-
DRN microcircuit modulate cocaine self-administration. In vivo optogenetics and, in parallel, Gq- or Gi-
DREADD in mice expressing Channelrhodopsin specifically in CRF neurons (ChR/Crh mice) will be used to
activate CRF inputs into the VTA or inhibit with archaerhodopsin. Microinjections CRFR1, CRFR2 and binding
protein antagonists and agonists into the VTA-DRN microcircuit will identify targets for preventing and
reversing effects of social defeat stress or optogenetic activation that escalate cocaine self-administration.
A special feature of the proposed work is the test of the hypothesis that social stress-escalated cocaine
self-administration is buffered in a sex-specific manner.
项目概要
当前具体目标的基本原理建立在一致的流行病学发现之上,即社会
压力对成瘾周期的所有阶段(从开始到升级再到复发)都起着至关重要的作用。这
社会压力和吸毒之间的密切联系是基于治疗吸毒受害者的急诊室的报告
暴力行为和刑事司法系统关于吸毒者实施的暴力犯罪的统计数据以及
流行病学证据和神经生物学数据。拟议方案要回答的首要问题
研究的主题是:社会压力与可卡因自我服用升级之间的机制联系是什么?我们的
特别强调促肾上腺皮质激素释放因子(CRF,通常称为 CRH)如何调节
中皮质边缘多巴胺(DA)系统。 CRF 系统一直受到人们的关注,不仅因为它
对于内分泌应激反应的启动至关重要,但其下丘脑外的定位和作用是
在应激障碍中具有重要意义,并且代表了治疗干预的潜在目标。
具体目标一检验了以下假设:高度厌恶的社会压力会放大强烈的回报
可卡因通过作用于后腹侧微电路中的 CRF 和多巴胺 (DA) 进行自我给药
被盖区(pVTA)到中缝背核(DRN)。神经解剖学管道追踪用于识别
与 DA 神经元的突触接触作为 CRF 输入的来源。在这些终端的体内微透析
微电路用于表征有助于应激诱导的动态神经适应
可卡因自我使用的升级(获取、维持、暴饮、复发)。
具体目标二检验以下假设:VTA 中特定 CRF 细胞群的激活和抑制
DRN 微电路调节可卡因自我给药。体内光遗传学以及并行的 Gq- 或 Gi-
特异性在 CRF 神经元中表达视紫红质通道蛋白的小鼠(ChR/Crh 小鼠)中的 DREADD 将用于
激活 CRF 输入到 VTA 或用古视紫红质抑制。显微注射 CRFR1、CRFR2 和结合
将蛋白质拮抗剂和激动剂注入 VTA-DRN 微电路将确定预防和治疗的靶点
扭转社会失败压力或光遗传学激活的影响,从而升级可卡因的自我给药。
拟议工作的一个特点是检验社会压力加剧可卡因的假设
自我给药以特定性别的方式缓冲。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KLAUS A MICZEK其他文献
KLAUS A MICZEK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KLAUS A MICZEK', 18)}}的其他基金
Neuropeptides, Social Stress and Drugs of Abuse
神经肽、社会压力和滥用药物
- 批准号:
8469849 - 财政年份:2011
- 资助金额:
$ 33.67万 - 项目类别:
Neuropeptides, Social Stress and Drugs of Abuse
神经肽、社会压力和滥用药物
- 批准号:
10059213 - 财政年份:2011
- 资助金额:
$ 33.67万 - 项目类别:
Neuropeptides, Social Stress and Drugs of Abuse
神经肽、社会压力和滥用药物
- 批准号:
8161767 - 财政年份:2011
- 资助金额:
$ 33.67万 - 项目类别:
Neuropeptides, Social Stress and Drugs of Abuse
神经肽、社会压力和滥用药物
- 批准号:
8891395 - 财政年份:2011
- 资助金额:
$ 33.67万 - 项目类别:
Neuropeptides, Social Stress and Drugs of Abuse
神经肽、社会压力和滥用药物
- 批准号:
10399771 - 财政年份:2011
- 资助金额:
$ 33.67万 - 项目类别:
Neuropeptides, Social Stress and Drugs of Abuse
神经肽、社会压力和滥用药物
- 批准号:
8426709 - 财政年份:2011
- 资助金额:
$ 33.67万 - 项目类别:
Neuropeptides, Social Stress and Drugs of Abuse
神经肽、社会压力和滥用药物
- 批准号:
8290211 - 财政年份:2011
- 资助金额:
$ 33.67万 - 项目类别:
Behavioral Neurobiology of Aggression, Alcohol, GABA, and 5-HT
攻击行为、酒精、GABA 和 5-HT 的行为神经生物学
- 批准号:
8506142 - 财政年份:2003
- 资助金额:
$ 33.67万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 33.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 33.67万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 33.67万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 33.67万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 33.67万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 33.67万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 33.67万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 33.67万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 33.67万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 33.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)